Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis.
CONCLUSIONS: Based on very low quality evidence, there is currently no evidence that any intervention is beneficial for primary biliary cholangitis. However, the follow-up periods in the trials were short and there is significant uncertainty in this issue. Further well-designed randomised clinical trials are necessary. Future randomised clinical trials ought to be adequately powered; performed in people who are generally seen in the clinic rather than in highly selected participants; employ blinding; avoid post-randomisation dropouts or planned cross-overs; should have sufficient follow-up period (e.g. five or 10 years or more); and use clinically important outcomes such as mortality, health-related quality of life, cirrhosis, decompensated cirrhosis, and liver transplantation. Alternatively, very large groups of participants should be randomised to facilitate shorter trial duration.
PMID: 28350426 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: Journals (General) Authors: Saffioti F, Gurusamy KS, Eusebi LH, Tsochatzis E, Davidson BR, Thorburn D Tags: Cochrane Database Syst Rev Source Type: research
More News: Bile | Cholestasis | Cirrhosis | Clinical Trials | Databases & Libraries | General Medicine | Hospital Management | International Medicine & Public Health | Liver | Liver Disease | Liver Transplant | Methotrexate | Primary Biliary Cirrhosis | Science | Transplants | Urology & Nephrology | WHO